EUVIMEDEUVIMED entdecken
Crossref

mRNA COVID ‐19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry

Omar Mansour, Sonia Hernandez-Diaz iD, Diego F Wyszynski iD

Pharmacoepidemiology and Drug Safety · 2023

DOI: 10.1002/pds.5600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von Omar Mansour und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Abortion, Spontaneous, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose mRNA COVID‐19 vaccines are used in pregnant populations whether advertently or inadvertently. However, evidence on the safety of these vaccines during pregnancy is limited. The objective of this study is to evaluate the effect of BNT162b2 (Pfizer‐BioNTech) and mRNA‐1273 (Moderna) vaccination during the first 20 weeks of gestation on the risk of spontaneous abortion (SAB).

Methods

All pregnant women who received at least one dose of BNT162b2 or mRNA‐1273 and enrolled in the COVID‐19 Vaccines International Pregnancy Exposure Registry (C‐VIPER) were prospectively followed from enrollment until 20 weeks of gestation, SAB, or loss to follow‐up. Baseline demographics, vaccination information, and pregnancy outcomes were collected via monthly online self‐administered questionnaires, vaccination certificates, and medical records. Life tables were used to calculate the cumulative risk of SAB. Cox regression was used to estimate the hazard ratio (HR) comparing the two vaccines groups stratified by country of residence and gestational age at enrollment.

Results

Among 6840 participants who received at least one dose of BNT162b2 or mRNA‐1273 at any time in pregnancy between Jan‐Sep, 2021, 2129 met the inclusion criteria (1576 received BNT162b2 and 553 mRNA‐1273). The two groups were balanced in terms of baseline characteristics. There were 37 SABs, with an overall 13.4% estimated cumulative risk by 20 weeks of gestation, which is similar to the expected risk in the population. The HR of SAB comparing mRNA‐1273 to BNT162b2 was 1.46 (95% CI: 0.66, 3.22).

Conclusion

The C‐VIPER data show no evidence that mRNA COVID‐19 vaccines increase the risk of SAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, SpontaneousCOVID-19PregnancyFemaleHumansCOVID-19 VaccinesBNT162 Vaccine2019-nCoV Vaccine mRNA-1273VaccinationRNA, MessengerRegistries

Stichwörter der Autor:innen

C-VIPERpharmacoepidemiologysafety

Substanzen

COVID-19 VaccinesBNT162 Vaccine2019-nCoV Vaccine mRNA-1273RNA, Messenger

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Pregistry, London, UK.

ORCID-Profile: Sonia Hernandez-Diaz, Diego F Wyszynski

Zitieren

APA

Mansour, O., Hernandez-Diaz, S., & Wyszynski, D. F. (2023). mRNA COVID ‐19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5600

Vancouver

Mansour O, Hernandez-Diaz S, Wyszynski DF. mRNA COVID ‐19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry. Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5600

BibTeX
@article{Mansour2023,
  author = {Mansour, Omar and Hernandez-Diaz, Sonia and Wyszynski, Diego F},
  title = {mRNA COVID ‐19 vaccination early in pregnancy and the risk of spontaneous abortion in an international pregnancy registry},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2023},
  doi = {10.1002/pds.5600}
}
Kostenlos starten →